177Lu-PSMA (R)進化におけるがん治療：本当に起こっているのか？

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)2023 · 69 citations
2. 2PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports2021 · 126 citations
3. 3Rucaparib for Metastatic Castration-Resistant Prostate Cancer2023 · 1 citations
4. 4Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer2021 · 2,655 citations
5. 5Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial2023 · 208 citations